https://www.mrc-lmb.cam.ac.uk/rlw/text/pdffiles/16647110.pdf

A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.

A method for performing intraocular brachytherapy and an apparatus for performing the same is disclosed. The apparatus preferably comprises a hand-held delivery device that advances a radiation source into an associated cannula or probe that is positioned adjacent the target tissue. The handpiece provides for shielded storage of the radiation source when retracted from the cannula and includes a slider mechanism for advancing and retracting the radiation source. The radiation source is mounted to a wire that has a flexible distal end and a relatively stiffer proximal end. A positioning system for the cannula is also disclosed.

Methods and apparatus for intraocular brachytherapy

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Benzimidazole quinolinones and uses thereof

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Dna-pk inhibitors

Compounds of Formula (I) that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.

Materials and methods to potentiate cancer treatment

Compound that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods of inhibiting the DNA-PK biological activity, methods of sensitizing cells the agents that cause DNA lesions, and methods of potentiating cancer treatment are disclosed.

Xanthones, thioxanthones and acridinones as dna-pk inhibitors

The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases

Kinase inhibitors and methods of use thereof

L'invention porte sur des composes qui inhibent la proteine kinase dependant de l'ADN, sur des compositions comprenant lesdits composes, sur des procedes d'inhibition de l'activite biologique d'ADN-PK, sur des procedes de sensibilisation des cellules, sur les agents qui provoquent les lesions de l'ADN et sur des procedes de potentialisation d'un traitement anticancereux.

Materiaux et procedes de potentialisation d'un traitement anticancereux

Cette invention, qui a trait a des composes inhibant une proteine kinase dependante de l'ADN (ADN-PK) ainsi qu'a des compositions renfermant ces composes, porte egalement sur des procedes d'inhibition de l'activite biologique de la ADN-PK, sur des procedes de sensibilisation de cellules a des agents provoquant des lesions de l'ADN et sur des methodes de potentialisation d'un traitement anticancereux.

Charles Todd Eary

Papers

Materials and methods to potentiate cancer treatment

Xanthones, thioxanthones and acridinones as dna-pk inhibitors

Kinase inhibitors and methods of use thereof

Materiaux et procedes de potentialisation d'un traitement anticancereux

Substances potentialisant un traitement anticancereux et methodes a cet effet